PhosPrint

Founded in 2019 and based at the Lefkippos Attica Technology Park, PhosPrint P.C. specializes in laser bioprinting, offering a proprietary technology that achieves 100% cell viability. The company contributes significantly to the advancement of biomedical research through the development of bioinks and antibody microarrays, enabling next-generation applications in life sciences and precision medicine.